An immune system protein could act as an early warning system for lung cancer, reveals research published ahead of print in the journal Thorax.
Lung cancer kills around 900,000 people every year, and can take 20 years or more to develop fully. But it is usually only picked up at an advanced stage, when the chances of successful treatment are slim.
As yet, there is no effective early warning system to detect the disease in its early treatable stages, and the dismal long term prospects of patients with lung cancer have changed little in the past 30 years.
The research team analysed blood (plasma) samples from 50 healthy volunteers and 104 people with different types of lung cancer.
They tested for autoantibodies - immune system proteins directed at the body’s own tissues in response to specific chemical signals in the body.
They looked in particular for a panel of seven autoantibodies, which are associated with ‘solid tumours,’ such a lung, breast, ovarian, and prostate cancers, and triggered when cancerous changes are taking place.
They found the presence of all seven autoantibodies, and very high levels of at least one of the seven in almost eight out of 10 samples taken from patients with confirmed lung cancer.
And these autoantibodies were found in eight out of the nine patients whose cancer had not infiltrated the lymph nodes, the body’s gatekeepers.
This indicates that the disease had not yet spread elsewhere and offers an 80% chance of a cure.
Only one healthy volunteer had more than one of these autoantibodies in their blood.
Other research has indicated that these autoantibodies can be picked up as early as five years before clinical symptoms start to show.
In a previous study, the researchers found abnormally high levels of specific autoantibodies in patients with breast cancer, prompting them to suggest that a test for these could be added to the screening programme. That study also showed that these autoantibodies were present before clinical symptoms appeared..
The authors argue that the lungs are especially sensitive to radiation, so repeated chest x-rays are not ideal for picking up lung cancer.
A blood test, on the other hand, is cheap compared with imaging techniques, and has no side effects. And the panel can be changed to include more or different autoantibodies for lung and other cancers.
They suggest that the blood test could be used for people at increased risk of developing the disease, such as smokers and passive smokers.
If they test positive, these people could then be referred for more detailed scans, such as computed tomography (CT) or magnetic resonance imaging (MRI), they suggest.
Source: British Medical Journal
Related stories:
Pre-eclampsia may be autoimmune disease
Biochemists at The University of Texas Medical School at Houston say they are the first to provide pre-clinical evidence that pregnancy-induced high blood pressure or pre-eclampsia may be an autoimmune disease. Their research could provide novel diagnostic and therapeutic possibilities for this intractable disease. Findings appear online in
Nature Medicine on July 27.
Protein complementarity may offer new insights into autoimmune diseases
The discovery of "complementary" antibodies against plasminogen in patients with blood vessel inflammation caused by anti-neutrophil cytoplasmic autoantibodies (ANCAs) may lead to new approaches to research, testing, and treatment of ANCA vasculitis and other autoimmune diseases, suggests a paper in the December
Journal of the American Society of Nephrology (
JASN).
B cells can act alone in autoimmune disease
B cells, the source of damaging autoantibodies, have long been thought to depend upon T cells for their activation and were not considered important in the initiation of autoimmune diseases like lupus or rheumatoid arthritis.
New research on pre-eclampsia in mice may have important implications for humans
In a new March of Dimes-funded study of pre-eclampsia, a serious and potentially deadly disorder that affects about 5 percent of pregnancies, researchers have found results in mice that may have important implications for diagnosis and treatment in humans.
Common bacteria activating natural killer T cells may cause autoimmune liver disease
A bacteria commonly found in soil and water triggered autoimmune symptoms in mice similar to those found in an incurable liver disease called Primary Biliary Cirrhosis (PBC). Reporting their findings in the May 15
Cell Host & Microbe, the multi-institutional research team said injecting laboratory mice with the bacterium – Novosphingobium aromaticivorans – prompted activation of Natural Killer T (NKT) cells, which were critical to initiating autoimmune processes that led to liver disease.
Autoantibodies and neuropsychiatric events in lupus
Systemic lupus erythematosus (SLE), commonly known as lupus, can affect nearly any part of the body, including the joints, skin, kidneys, heart, nervous system, and brain. Along with joint pain, muscle pain, unexplained fever, extreme fatigue, and skin rashes, neurologic and psychiatric events often accompany this autoimmune disease. Depending on the study, between 37 and 95 percent of SLE patients experience signs and symptoms of neuropsychiatric (NP) disease. Determining the correct attribution to NP events is a challenge when managing nervous system disease in individual SLE patients, as well as a critical factor in selecting the right treatment and evaluating progress. For guidance in these decisions, doctors need reliable biomarkers -- which, as dedicated researchers know, have proven difficult to find.
Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring
New research from the UC Davis M.I.N.D. Institute shows that an interaction between fetal brain cells and maternal antibodies could be linked with the repetitive behavior – also called stereotypies – that is characteristic of autism. While additional studies are needed to confirm the outcome, this result leads investigators to suspect that brain-directed antibodies during the prenatal period could be a causal factor for the disorder. The study appears online now and will be published in a future issue of Brain, Behavior and Immunity.
Study tests oral insulin to prevent type 1 diabetes
University of Florida researchers have begun a clinical study of oral insulin to prevent or delay type 1 diabetes in people at risk for the disease.